Seek Returns logo

Command Palette

Search for a command to run...

AZN vs. RHHBF: A Head-to-Head Stock Comparison

Here's a clear look at AZN and RHHBF, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolAZNRHHBF
Company NameAstraZeneca PLCRoche Holding AG
CountryUnited KingdomSwitzerland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization315.47 billion USD331.18 billion USD
CurrencyUSDUSD
ExchangeNYSEOTC Markets OTCQX
Listing DateMay 12, 1993August 3, 2012
Security TypeADRCommon Stock

AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RHHBF is a standard domestic listing.

AZN's market capitalization stands at 315.47 billion USD, while RHHBF's is 331.18 billion USD, indicating their market valuations are broadly comparable.

AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RHHBF is a standard domestic listing.

Historical Performance

This chart compares the performance of AZN and RHHBF by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

AZN vs. RHHBF: Growth of a $10,000 investment over the past five years.

Historical Performance at a Glance

SymbolAZNRHHBF
5-Day Price Return7.09%1.76%
13-Week Price Return12.68%--
26-Week Price Return36.97%--
52-Week Price Return52.31%--
Month-to-Date Return4.26%1.05%
Year-to-Date Return11.07%0.51%
10-Day Avg. Volume1.68M1.27M
3-Month Avg. Volume1.31M1.11M
3-Month Volatility27.28%--
Beta1.071.46

With betas of 1.07 for AZN and 1.46 for RHHBF, both stocks show similar sensitivity to overall market movements.

Profitability

Return on Equity (TTM)

AZN

22.68%

Pharmaceuticals Industry
Max
39.28%
Q3
20.27%
Median
12.91%
Q1
5.11%
Min
-14.55%

In the upper quartile for the Pharmaceuticals industry, AZN's Return on Equity of 22.68% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RHHBF

--

Pharmaceuticals Industry
Max
39.28%
Q3
20.27%
Median
12.91%
Q1
5.11%
Min
-14.55%

Return on Equity data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

AZN

17.41%

Pharmaceuticals Industry
Max
41.87%
Q3
22.21%
Median
14.64%
Q1
9.09%
Min
-8.35%

AZN's Net Profit Margin of 17.41% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

RHHBF

--

Pharmaceuticals Industry
Max
41.87%
Q3
22.21%
Median
14.64%
Q1
9.09%
Min
-8.35%

Net Profit Margin data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

AZN

23.40%

Pharmaceuticals Industry
Max
43.61%
Q3
25.68%
Median
18.69%
Q1
12.76%
Min
-4.35%

AZN's Operating Profit Margin of 23.40% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

RHHBF

--

Pharmaceuticals Industry
Max
43.61%
Q3
25.68%
Median
18.69%
Q1
12.76%
Min
-4.35%

Operating Profit Margin data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

SymbolAZNRHHBF
Return on Equity (TTM)22.68%--
Return on Assets (TTM)9.15%--
Net Profit Margin (TTM)17.41%--
Operating Profit Margin (TTM)23.40%--
Gross Profit Margin (TTM)81.31%--

Financial Strength

Current Ratio (MRQ)

AZN

0.94

Pharmaceuticals Industry
Max
6.79
Q3
3.59
Median
2.17
Q1
1.38
Min
0.80

AZN's Current Ratio of 0.94 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RHHBF

--

Pharmaceuticals Industry
Max
6.79
Q3
3.59
Median
2.17
Q1
1.38
Min
0.80

Current Ratio data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

AZN

0.61

Pharmaceuticals Industry
Max
1.60
Q3
0.76
Median
0.27
Q1
0.03
Min
0.00

AZN's Debt-to-Equity Ratio of 0.61 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RHHBF

--

Pharmaceuticals Industry
Max
1.60
Q3
0.76
Median
0.27
Q1
0.03
Min
0.00

Debt-to-Equity Ratio data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

AZN

10.25

Pharmaceuticals Industry
Max
154.61
Q3
70.06
Median
13.25
Q1
2.72
Min
-27.02

AZN's Interest Coverage Ratio of 10.25 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

RHHBF

--

Pharmaceuticals Industry
Max
154.61
Q3
70.06
Median
13.25
Q1
2.72
Min
-27.02

Interest Coverage Ratio data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

SymbolAZNRHHBF
Current Ratio (MRQ)0.94--
Quick Ratio (MRQ)0.72--
Debt-to-Equity Ratio (MRQ)0.61--
Interest Coverage Ratio (TTM)10.25--

Growth

Revenue Growth

AZN vs. RHHBF: A comparison of their Revenue Growth across different time periods.

Revenue Growth at a Glance

SymbolAZNRHHBF
Revenue Growth (MRQ vs Prior YoY)4.11%--
Revenue Growth (TTM vs Prior YoY)8.63%--
3-Year Revenue CAGR9.82%--
5-Year Revenue CAGR17.15%--

EPS Growth

AZN vs. RHHBF: A comparison of their EPS Growth across different time periods.

EPS Growth at a Glance

SymbolAZNRHHBF
EPS Growth (MRQ vs Prior YoY)55.36%--
EPS Growth (TTM vs Prior YoY)45.41%--
3-Year EPS CAGR45.90%--
5-Year EPS CAGR21.88%--

Dividend

Dividend Yield (TTM)

AZN

1.58%

Pharmaceuticals Industry
Max
6.07%
Q3
2.91%
Median
1.74%
Q1
0.00%
Min
0.00%

AZN's Dividend Yield of 1.58% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

RHHBF

0.00%

Pharmaceuticals Industry
Max
6.07%
Q3
2.91%
Median
1.74%
Q1
0.00%
Min
0.00%

RHHBF currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

AZN vs. RHHBF: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

AZN

48.62%

Pharmaceuticals Industry
Max
165.20%
Q3
80.63%
Median
43.56%
Q1
0.00%
Min
0.00%

AZN's Dividend Payout Ratio of 48.62% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RHHBF

0.00%

Pharmaceuticals Industry
Max
165.20%
Q3
80.63%
Median
43.56%
Q1
0.00%
Min
0.00%

RHHBF has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

AZN vs. RHHBF: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

SymbolAZNRHHBF
Dividend Yield (TTM)1.58%0.00%
Dividend Payout Ratio (TTM)48.62%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

AZN

30.74

Pharmaceuticals Industry
Max
45.36
Q3
26.62
Median
19.14
Q1
14.11
Min
3.63

A P/E Ratio of 30.74 places AZN in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company's future growth.

RHHBF

--

Pharmaceuticals Industry
Max
45.36
Q3
26.62
Median
19.14
Q1
14.11
Min
3.63

P/E Ratio data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

AZN

5.35

Pharmaceuticals Industry
Max
8.75
Q3
5.31
Median
2.62
Q1
2.00
Min
0.86

AZN's P/S Ratio of 5.35 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

RHHBF

--

Pharmaceuticals Industry
Max
8.75
Q3
5.31
Median
2.62
Q1
2.00
Min
0.86

P/S Ratio data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

AZN

5.80

Pharmaceuticals Industry
Max
10.12
Q3
5.40
Median
2.62
Q1
1.54
Min
0.63

AZN's P/B Ratio of 5.80 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company's net assets, a valuation that hinges on its ability to generate superior profits.

RHHBF

--

Pharmaceuticals Industry
Max
10.12
Q3
5.40
Median
2.62
Q1
1.54
Min
0.63

P/B Ratio data for RHHBF is currently unavailable.

AZN vs. RHHBF: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

SymbolAZNRHHBF
Price-to-Earnings Ratio (TTM)30.74--
Price-to-Sales Ratio (TTM)5.35--
Price-to-Book Ratio (MRQ)5.80--
Price-to-Free Cash Flow Ratio (TTM)36.25--